Page 3 - Hammersmith Functional Motor Scale Expanded News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Genentech shares positive two-year data for Evrysdi in spinal muscular atrophy study

Genentech shares positive two-year data for Evrysdi in spinal muscular atrophy study
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Levi garrawayClaudia chiribogaWorld muscle societyColumbia university medical centerColumbia university medicalHammersmith functional motor scale expanded

Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Positive new data for Roche s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)

Investegate announcements from F. Hoffmann-La Roche Ltd, Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)

New yorkUnited statesColumbia universityUnited kingdomSileia urechLevi garrawayLoren kalmClaudia chiribogaRoche evrysdiKarsten kleineNathalie altermattSociety for medicines researchDepartment of neurologyToddler developmentBritish pharmacological societyDrug administration

Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress

- Positive 24-month data from ongoing Phase 2 TOPAZ trial extension supports potential benefit of apitegromab for patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)- Actively enrolling in pivotal Phase 3 SAPPHIRE clinical trial for apitegromab- Discovery pipeline advancements made for LTBP-TGFβ1 target to tre.

United kingdomNagesh mahanthappaTed mylesAriane lovellRushmie nofsingerExchange commissionScholar rock incInternational congress on neuromuscular diseasesScholar rock holding corporationMuscular atrophyScholar rockHammersmith functional motor scale expandedFounding chief executive officerMonth phaseData support potential benefitClinical care meeting

New data for Roche s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)

Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH. | March 16, 2022

United kingdomUnited statesNathalie meetzLaurent servaisLevi garrawayLoren kalmMuscular dystrophy associationSociety for medicines researchToddler developmentBritish pharmacological societyDrug administrationHead of global product developmentOxford neuromuscular centreEuropean medicines agencyRoche groupOffice of orphan products development

Roche s Evrysdi® shows long-term efficacy in spinal muscular atrophy

New data demonstrates the long-term safety and efficacy of Evrysdi® (risdiplam) in a broad population of people with spinal muscular atrophy.

United kingdomLaurent servaisLevi garrawayRoche evrysdiMuscular dystrophy associationDrug administrationHead of global product development at rocheOxford neuromuscular centreScientific conferencePaediatric neuromuscular diseasesNeuromuscular centreMotor function measureRevised upper limb moduleHammersmith functional motor scale expandedChief medical officerGlobal product development